ArticlePediatric cardiology2013
Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study.
Article in Pediatric cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Neoadjuvant chemotherapy and perioperative cardiotoxicity.Journal of anesthesia and translational medicine · 2024Review
- Development and Phenotype of Heart Failure in Long-Term Survivors of Childhood Cancer: The CVSS Study.Journal of the American Heart Association · 2023Article
- Cardio-Oncology in Childhood: State of the Art.Current oncology reports · 2022Review
- Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Cardiovascular Complications in Major 21st Century Viral Epidemics and Pandemics: an Insight into COVID-19.Current cardiology reviews · 2021Review
- Cranial Irradiation in Childhood Acute Lymphoblastic Leukemia Is Related to Subclinical Left Ventricular Dysfunction and Reduced Large Artery Compliance in Cancer Survivors.Journal of clinical medicine · 2019Article
- Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2018Article
- Use of speckle tracking in the evaluation of late subclinical myocardial damage in survivors of childhood acute leukaemia.The international journal of cardiovascular imaging · 2018Article
- Prevention of cardiotoxicity among survivors of childhood cancer.British journal of clinical pharmacology · 2017Review
- Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Current treatment options in cardiovascular medicine · 2016Review
- Cardiovascular Complications of Cranial and Neck Radiation.Current treatment options in cardiovascular medicine · 2016Review
- Cardiotoxicity of anthracycline therapy: current perspectives.Archives of medical science : AMS · 2016Article
- Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFup.PloS one · 2016Article
- Cardiovascular disease in adult survivors of childhood cancer.Annual review of medicine · 2015Review
- Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Paediatric drugs · 2014Review
- Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.Current treatment options in cardiovascular medicine · 2014Article
- Treatment-related cardiotoxicity in survivors of childhood cancer.Nature reviews. Clinical oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Anthracycline-treated childhood cancer survivors experience cardiac damage that results in decreased left ventricular (LV) mass, leading to increased LV wall stress, which underlies their greater risk of cardiomyopathy. Many of these survivors also are at risk of growth hormone (GH) abnormalities from cranial irradiation exposure, although it is unknown whether such exposure is associated with cardiotoxicity. Echocardiograms and insulin-like growth factor-1 (IGF-1), a marker of GH, were measured in 130 anthracycline-treated childhood cancer survivors, 59 of whom had been exposed to cranial irradiation, a mean 10 years after their cancer diagnosis. Echocardiographic parameters and IGF-1 were standardized relative to age or body surface area using data from sibling control subjects and expressed as the percentage difference from normal values. The results showed that after adjustment for other risk factors, survivors exposed to cranial irradiation had an additional 12 % decrease in LV mass compared with unexposed survivors (P < 0.01) and an additional 3.6 % decrease in LV dimension (P = 0.03). Survivors exposed to cranial irradiation also had a 30.8 % decrease in IGF-1 relative to normal values, which was greater than the 10.5 % decrease in unexposed survivors (P < 0.01). The above findings led us to conclude that in anthracycline-treated childhood cancer survivors a mean 10 years after their diagnosis, those with cranial irradiation exposure had significantly greater decreases in LV mass and dimension. Because cranial irradiation also was associated with decreased IGF-1, it is possible that GH deficiencies mediated this effect, suggesting that GH replacement therapy may help to prevent the development of cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.